Cov tshuaj polypeptideTB 500 tshuaj tsuagyog ib yam khoom uas ua rau polypeptide TB 500 uas muaj zog lom lom rau hauv daim ntawv tshuaj tsuag. Hom tshuaj tsuag no muab kev yooj yim thiab muaj peev xwm tshiab rau nws daim ntawv thov, uas ua rau nws nyiam ntau yam hauv thaj chaw biomedicine. Cov neeg ncaws pob tuaj yeem nqa nws nrog lawv thiab sai sai nrog kev raug mob sai sai thaum lub sijhawm kev cob qhia lossis kev sib tw so, txo lub sijhawm ncua vim kev raug mob. Hais txog kev saib xyuas hauv tsev, nws yog qhov tsim nyog rau kev tswj hwm hauv tsev txhua hnub ntawm qhov txhab me me, kub hnyiab lossis mob rwj (xws li mob ntshav qab zib taw) kom txo tau txoj kev pheej hmoo ntawm kev kis kab mob. Rau kev kho mob kev tshaj lij, hauv cov chaw kho mob lossis chaw kho mob, nws tuaj yeem siv los ua ib txoj hauv kev kho mob, ua ke nrog lwm cov kev kho mob kom ceev cov neeg mob rov qab los. Hauv lwm qhov chaw, xws li kev saib xyuas kev zoo nkauj, qee qhov kev tshawb fawb tshawb nrhiav nws lub peev xwm los txhim kho cov tawv nqaij (xws li kev ruaj khov thiab elasticity), uas yuav nthuav mus rau kev tiv thaiv kev laus los yog kev kho mob zoo nkauj.
Peb cov khoom Form
TB 500 COA
Cov tshuaj polypeptideTB 500 tshuaj tsuag, raws li tus neeg sawv cev tshiab tshiab, qhia tau hais tias muaj txiaj ntsig zoo hauv ntau qhov kev thov nrog nws cov qauv tsim tshwj xeeb molecular thiab ntau lub hom phiaj ua haujlwm.
Kev kho kab mob plawv: lub hom phiaj meej, tsis yog -kev tswj hwm
Hauv cov kab mob plawv xws li myocardial infarction thiab atherosclerosis, cov kev kho mob ib txwm muaj xws li kev phais mob lossis tshuaj hauv qhov ncauj muaj teeb meem xws li mob siab thiab tsis muaj bioavailability. Kev xa tshuaj tsis yog tshuaj yog ua tiav los ntawm kev txau cov tawv nqaij hauv zos, nrog rau qhov hnyav molecular tsuas yog 889.01 Da. Nws cov khoom me me tso cai rau nws nkag mus rau ntawm daim tawv nqaij sai sai thiab ua ncaj qha rau cov hlwb puas hlwb lossis vascular endothelial.
Kev sim cov ntaub ntawv qhia tau hais tias nyob rau hauv BALB / c nas tus qauv myocardial infarction, niaj hnub tshuaj tsuag hauv zos ntawm 15 μ g / 30 μ L TB 500 tshuaj rau 10 hnub sib law liag tuaj yeem txhawb nqa angiogenesis, txo qis myocardial infarction cheeb tsam los ntawm 37%, thiab txhim kho cov kev ua haujlwm plawv (xws li 2%. Txoj kev tswj hwm no zam qhov mob thiab kab mob txaus ntshai ntawm kev txhaj tshuaj hauv cov hlab ntsha, thiab cov neeg mob tuaj yeem ua haujlwm rau lawv tus kheej, tshwj xeeb tshaj yog tsim nyog rau cov xwm txheej hauv tsev.
Kev kho mob kev ua kis las: nqa tau yooj yim thiab ua tau zoo, ua kom lub voj voog rov zoo
Cov neeg ncaws pob lossis cov neeg nyiam kev tawm dag zog feem ntau ntsib kev raug mob hnyav xws li cov leeg nqaij thiab ligament kua muag. Nws txoj kev yooj yim yog tshwm sim nyob rau hauv nws qhov pib nrawm thiab txav tau yooj yim. Cov khoom xyaw nquag Ac-T 417-23 tuaj yeem cuam tshuam txoj kev taw qhia Akt, txo cov cell apoptosis, thiab txhawb txoj kev ciaj sia.
Hauv cov qauv sib tw nees, ib qho kev txhaj tshuaj ib zaug ntawm 10 mg TB 500 tuaj yeem txo lub sijhawm kho cov leeg, thaum cov tshuaj tsuag tuaj yeem ua tiav kev tswj hwm tshuaj ntau dua los ntawm kev tshuaj tsuag hauv zos (piv txwv li, txhua qhov tshuaj tsuag muaj 5 mg TB 500), thiab tsis tas yuav tsum muaj cov kws kho mob ua haujlwm. Tsis tas li ntawd, nws cov khoom siv hmoov cia khoom (-20℃txog li 3 xyoos) thiab cov yam ntxwv ntawm kev thauj mus los hauv chav sov ua rau nws yog ib qho tshuaj zoo tshaj plaws rau kev ua kis las thaum muaj kev sib tw sab nraum zoov.
Kev kho mob ntawm daim tawv nqaij: ntau yam kev sib koom tes, ua kom yooj yim rau kev laus
Cov qhov txhab mob ntev (xws li mob ntshav qab zib ko taw ulcers) feem ntau ua rau kev kho mob qeeb vim tsis txaus angiogenesis thiab cov tshuaj tiv thaiv ntau dhau. Accelerate kho los ntawm ib tug triple mechanism:
Txhawb nqa keratinocyte tsiv teb tsaws: Kev sim tau pom tias TB 500 daws ntawm 15-25 μ g / mL tuaj yeem txhim kho cov calcium ion ntws hauv cov cell, qhib purinergic P2 receptors, thiab nce cell migration ceev los ntawm 40%;
Txhawb nqa angiogenesis: Upregulate VEGF qhia, tsim ib tug neovascularization network nyob rau hauv cov ntaub so ntswg dermal, thiab muab zaub mov txaus rau qhov txhab;
Anti-inflammatory effect: inhibits qhov tso tawm ntawm inflammatory yam xws li TNF - thiab txo qhov txhab liab thiab o cov tsos mob.
Cov kws kho mob pom tau tias cov neeg mob ntshav qab zibTB 500 tshuaj tsuag(xws li 10 mg TB 500) ntawm ko taw rwj txhua hnub, tus nqi kho tau hauv ob lub lis piam yog 65% siab dua li ntawm pawg hnav khaub ncaws ib txwm muaj, thiab tsis tas yuav hloov khaub ncaws ntau zaus, txo tus nqi kho mob.
Kev kho mob txhua hnub: kev nyab xeeb thiab maj mam, haum rau ntau tus neeg
Txoj kev yooj yim kuj tshwm sim hauv nws txoj kev nyab xeeb thiab kev siv tau. Raws li ib tug hluavtaws molecule ntawm thymosin 4 active fragment, nws tsis muaj tsiaj derived cov khoom xyaw, txo cov kev pheej hmoo ntawm kev ua xua. Hauv kev sim tsiaj, tsis muaj kev cuam tshuam tshuaj lom ntawm ib koob ntawm 40 mg / kg (sib npaug rau 2800 mg rau 70 kg neeg laus), uas yog ntau dua li cov tshuaj kho mob (10-50 mg ib hnub).
Tsis tas li ntawd, nws cov dej solubility nce mus txog 247.5 mg / mL, ua kom yooj yim los npaj cov kev daws teeb meem sib txawv kom tau raws li tus kheej xav tau. Piv txwv li, cov neeg laus tuaj yeem tiv thaiv kev laus ntawm cov hlab plawv los ntawm cov tshuaj tsuag tsis tshua muaj siab (5 mg / zaug), thaum cov neeg nyiam kev noj qab haus huv tuaj yeem siv cov kev npaj siab siab (25 mg / sijhawm) txhawm rau txhim kho cov leeg nqaij.
Yooj yim rau kev khiav lag luam, sij hawm-txuag thiab ua haujlwm- txuag
Cov tshuaj tsuag tsim ua kom yooj yim rau kev siv yam tsis muaj kev ua haujlwm nyuaj lossis kev cob qhia kev tshaj lij. Cov neeg siv tsuas yog yuav tsum tau nias lub nozzle kom sib npaug ntawm qhov chaw puas, zam qhov teeb meem ntawm daim ntawv thov tsis sib xws lossis rov ua dua ntawm cov tshuaj pleev ib ce. Rau thaj chaw loj lossis qhov nyuaj mus txog qhov chaw (xws li lub nraub qaum thiab lub qhov sib koom ua ke), cov tshuaj tsuag muaj qhov ua tau zoo dua qub, uas tuaj yeem ua tiav kev tu thiab tu sai sai.
Kev nkag mus tau zoo thiab nqus tau sai
Cov tshuaj tsuag hom disperses TB 500 rau hauv cov khoom zoo los ntawm kev siv tshuab micronization, ua rau thaj chaw sib cuag nrog cov tawv nqaij lossis cov mucosa, thiab txhawb kev nkag mus ntawm cov khoom xyaw. Some products may combine transdermal absorption technologies (such as liposome encapsulation and nanocarriers) to further break through the skin barrier, allowing active ingredients to reach target tissues faster and shorten the onset time. Qhov no yog qhov tseem ceeb tshwj xeeb rau kev raug mob hnyav lossis cov xwm txheej uas yuav tsum tau kho cov tsos mob sai, xws li kev rov ua haujlwm tom qab kev tawm dag zog thiab kev saib xyuas tom qab phais.
Qhov yooj yim ntawm TB 500 tsis tuaj yeem sib cais los ntawm nws txoj kev ua tiav:
Cov yam ntxwv no ua rau nws ua lub luag haujlwm zoo hauv chav xwm txheej ceev, chaw ua kis las, kev saib xyuas hauv tsev, thiab lwm yam xwm txheej, dhau los ua ib qho piv txwv tseem ceeb ntawm cov tshuaj peptide hloov ntawm chav kuaj mus rau kev siv tshuaj kho mob.
Cov ntsiab lus ntawm Pharmacokinetic Parameters
Bioavailability: Lub bioavailability ntawm cov tshuaj pleev ib ce yog cuam tshuam los ntawm tej yam xws li daim ntawv thov chaw thiab cov tawv nqaij mob, tab sis nws yuav ua tau zoo heev los ntawm optimizing lub formulation (xws li, ntxiv kev nkag mus rau enhancers).
Pom meej Volume of Distribution (Vd): TB 500 muaj Vd loj, qhia txog nws qhov kev faib tawm thoob plaws hauv cov ntaub so ntswg, ua rau nws tsim nyog rau kev kho mob hauv zos.
Clearance (CL): Kev tshem tawm nruab nrab tswj cov ntshav cov tshuaj kom ruaj khov, tsis txhob noj ntau zaus.
Ib nrab-Lub Neej (t1/2): Ib nrab ntawm ib nrab-Lub neej ua kom ob leeg ua haujlwm tau zoo thiab zam kev sib sau tshuaj.
Pharmacokinetic tsom xam
Cov ntsiab lus tseem ceeb ntawmTB 500 tshuaj tsuagyog cov active fragment ntawm thymosin beta 4 (TB-4), uas muaj ib tug molecular hnyav ntawm tsuas yog 889.01 Da thiab siab permeability thiab lom lom. Cov nram qab no systematically elaborates ntawm nws nyob rau hauv vivo cov txheej txheem thiab cov yam ntxwv los ntawm plaub yam: nqus, faib, metabolism, thiab excretion, ua ke nrog cov ntaub ntawv sim thiab pharmacokinetic cov hauv paus ntsiab lus.
Kev tswj hwm tsis muaj kev cuam tshuam yog ua tiav los ntawm kev txau ntawm daim tawv nqaij hauv zos, zam qhov mob thiab kev pheej hmoo ntawm kev kis kab mob cuam tshuam nrog kev txhaj tshuaj intravenous. Nws cov khoom me me molecule (molecular hnyav<1000 Da) allow it to quickly penetrate the skin barrier and enter the bloodstream. Experiments have shown that in BALB/c mouse models, after local spraying, it can quickly distribute to tissues such as myocardium and skeletal muscle, indicating high absorption efficiency. In addition, its water solubility reaches 247.5 mg/mL, making it easy to prepare solutions of different concentrations to meet personalized drug delivery needs. User feedback also confirms that there is no irritation after spraying, and the effect is rapid, suitable for immediate care of sports injuries or chronic wounds.
Tom qab txau, nws tuaj yeem tsom cov ntaub so ntswg puas. Lub mechanism yuav cuam tshuam nrog cov hauv qab no:
Angiogenesis induction:
Los ntawm upregulating VEGF qhia, nws txhawb angiogenesis nyob rau hauv cov ntaub so ntswg dermal thiab muab zaub mov txaus rau qhov txhab. Hauv cov qauv mob ntshav qab zib taw rwj, tom qab txau, cov ntshav ntws hauv zos ntawm qhov txhab tau nce ntxiv, thiab kev kho ceev tau nce 65%.
Txhim kho cell migration:
Cov kev sim tau pom tias nws tuaj yeem ua kom cov calcium ion ntws mus rau hauv lub cev, nce qhov nrawm ntawm keratinocytes los ntawm 40%, thiab ua kom lub qhov txhab kaw.
Organizational affinity:
Nws muaj qhov tshwj xeeb affinity rau cov ntaub so ntswg xws li myocardium thiab skeletal leeg, uas muaj peev xwm tsim muaj siab concentration aggregates hauv zos thiab txhim kho cov teebmeem.
Nws cov metabolic stability yog ib qho txiaj ntsig tseem ceeb hauv nws cov tshuaj pharmacokinetics. Nws cov hmoov zoo tuaj yeem khaws cia rau 1 xyoos ntawm -80 degree, zam qhov poob ntawm kev ua haujlwm los ntawm kev rov khov dua -thaw cycles. Hauv lub cev, nws tsuas yog metabolized los ntawm daim siab, tab sis kev sim tau pom tias nws cov metabolites muaj kev ua haujlwm qis thiab ib nrab-lub neej (kwv yees li ob peb teev mus rau ob peb hnub), uas tuaj yeem tswj cov ntshav cov tshuaj muaj zog. Tsis tas li ntawd, tsis muaj qhov tseem ceeb induction lossis inhibition ntawm cytochrome P450 (CYP450) enzymes, thiab kev pheej hmoo ntawm kev sib cuam tshuam ntawm cov tshuaj yog tsawg thaum siv nrog lwm cov tshuaj.
Cov tshuaj no thiab nws cov metabolites feem ntau yog tawm los ntawm ob lub raum ( zis) thiab kua tsib (feces). Kev sim cov ntaub ntawv qhia tau hais tias kwv yees li 60% ntawm cov koob tshuaj tau tso tawm los ntawm cov zis hauv 48 teev tom qab kev tswj hwm ib zaug, thaum qhov seem yog tawm los ntawm cov quav. Txoj kev no ntau - channel excretion tuaj yeem zam qhov sib xyaw ntawm cov tshuaj hauv lub cev thiab txo qhov kev pheej hmoo ntawm toxicity. Kev sim kev nyab xeeb kuj tau lees paub tias txawm tias ntawm ib koob tshuaj 40 mg / kg (sib npaug rau 2800 mg rau 70 kg cov neeg laus), tsis muaj kev cuam tshuam tshuaj lom, uas yog ntau dua li cov tshuaj kho mob (10-50 mg ib hnub).
Cim npe nrov: tb 500 spray, Tuam Tshoj tb 500 spray manufacturers, lwm tus neeg
